EAU 2024: Bladder cancer latest

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Multiple myeloma in a resource constrained setting

Pembrolizumab a promising option for MIUC patients after radical surgery

Updates on lung cancer from WCLC and ESMO 2023

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC

Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of aRCC

Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma